Optimalisatie van de werkingsprocessen van het Bijzonder ... - KCE

More documents

Recommendations

Info

204 Special Solidarity Fund KCE Reports 133 9.17.2 France The assessment of the cases is based on telephone interviews with experts and desk research. The desk research consisted from an in-depth analysis of the Nomenclature database, available at www.ameli.fr. This database contains all products and services that are reimbursed under the Assurance Maladie Obligatoire. The Excel sheet uses the Codification language which is used by the French nomenclature of Medicines, Products and Services. The nomenclature distinguishes between: • CIP codes (Club Inter Pharmaceutique), which reflect the Marketing Authorisation of a specific medicine and ensure the traceability of drugs. CIP codes, consisting from 7 numbers, are administered by the Club Inter Pharmaceutique and the AFSSAPS. CIP codes can be further split up between: o Drugs, for which only so-called collectivités (hospitals, residential homes for the elderly…) are recognized agents; o Drugs, that are remboursable aux assurés sociaux and/or agree aux collectivités. • UCD codes (Communes de Dispensation Utilisées à l’hôpital) are only attributed to medicines that are used within hospitals or other health institutions. The UCD codification is still in use as the exchange standard regarding reimbursements of services (tarification à l’activité, T2A) and so-called rétrocession (medicines that are prescribed and purchased intra muros for patients that are not hospitalized). In case of rétrocession, the costs of drugs are not charged on the hospital budget. Also UCD codes are being developed and administered by the CIP.
KCE Reports 133 Special Solidarity Fund 205 Name Active substance Indication CIP UCD Source Adagen Pegademase bovine a type of SCID (severe combined immunodeficiency syndrome) caused by the chronic deficiency of the adenosine deaminase (ADA) enzyme Vidaza Azacitidine myelodysplastic syndrome Kuvan sapropterin dihydrochloride Cellcept Mycophenolate mofetil phenylketonuria (PKU) - tetrahydrobiopterin defiency auto immunology diseases - neophrotic syndromegreffe pulmonaire-greffe des ilots de Langhermans Mabthera Rituximab Heamatologic oncology (leukemia - lymphoma) Avastin Bevacizumab brain tumors (glioblastoma) - eye disorders-cancer colon métatasé 2ième intention-tumeur de l'ovaire Not found= not reimbursed under the statutory Not found= not reimbursed under the health insurance (l'Assurance Maladie statutory health insurance (l'Assurance obligatoire) Maladie obligatoire) CIP: Médicament NON Remboursable aux Assurés Sociaux (A) / Agrées aux collectivités: sinds 01/2009 CIP: Médicament NON Remboursable aux Assurés Sociaux (A) / Agrées aux collectivités: sinds 04/2009 CIP: depending on the product; Homologation Assurés Sociaux (A) - 100% - since 10/01/2006 (re-examined in 2013) + Homologation Collectivité C: since 10/01/2006 CIP: Médicament NON Remboursable aux Assurés Sociaux (A) / Agrées aux collectivités C: since 1998 CIP: Médicament NON Remboursable aux Assurés Sociaux (A) / Agrées aux collectivités C: sinds 07/2005 UCD: Rétrocession: 100% - sinds 18/02/2009 - Médicament Non facturable en sus de la TAA UCD: Rétrocession: 65% (sinds 24/04/2009) - Médicament Non facturable en sus de la TAA Not found= not reimbursed under the statutory health insurance (l'Assurance Maladie obligatoire) UCD: Rétrocession: 100% (since 11/05/2005) - TAA: 11/05/2005 UCD: Médicament Non Remboursable au titre de la rétrocession - TAA: 09/2005 Mrs. Isabelle Chenney + Nomenclature Assurance Maladie Mrs. Isabelle Chenney + Nomenclature Assurance Maladie Mrs. Isabelle Chenney + Nomenclature Assurance Maladie (Base des médicament et informations tarifaires) Mrs. Isabelle Chenney + Nomenclature Assurance Maladie (Base des médicament et informations tarifaires) Mrs. Isabelle Chenney + Nomenclature Assurance Maladie (Base des médicament et informations tarifaires) Mrs. Isabelle Chenney + Nomenclature Assurance Maladie (Base des médicament et informations tarifaires) Bi-myconase and/or sucraid Ointmenst, disinfectants, glucamylase & invertase (saccharase) enzyme deficiency sucrose isomaltase Not found in the nomenclature Not found in the nomenclature No information found painkillers, tape, food supplements epidermolysis bullosa - ichthyosis Not found in the nomenclature Not found in the nomenclature No information found Implantable cardiac valves (aortic valves) degenerative valve disease (aged persons) Not found in the nomenclature Not found in the nomenclature No information found Implantable pulmonary valves congenital cardiac malformations (children) Patients who have no remaining auditory nerves (ex. Not found in the nomenclature Not found in the nomenclature No information found Brainstem implant Bilateral vestibular schwannomas tumors on both balance nerves) Not found in the nomenclature Not found in the nomenclature No information found Not found= not reimbursed under the statutory Not found= not reimbursed under the Nomenclature Assurance Maladie: Neuro stimulator of the stomach Severe gastro paresis health insurance (l'Assurance Maladie statutory health insurance (l'Assurance Liste des prestations et des Services obligatoire) Maladie obligatoire) (LPP) Flolan époprosténol pulmonary hypertension CIP: Médicament NON Remboursable aux Assurés Sociaux (A) / Agrées aux collectivités UCD: Rétrocession: 100% (sinds 1/05/2004) - TAA: 05/2005 Mrs. Isabelle Chenney + Nomenclature Assurance Maladie (Base des médicament et informations tarifaires) Legende CIP (Club Inter Pharmaceutique): remboursables aux assurés sociaux et agréés aux collectivités (maisons de rétraites, hôpitaux) UCD (unités communes de dispensation): rétrocédés et facturables en sus des GHS par les établissements de santé
Page 1 and 2:
Optimalisatie van de werkingsproces
Page 3 and 4:
Optimalisatie van de werkingsproces
Page 5 and 6:
KCE reports 133A Bijzonder Solidari
Page 7 and 8:
Page 9 and 10:
Page 11 and 12:
Page 13 and 14:
Page 15 and 16:
Page 17:
Page 20 and 21:
2 Special Solidarity Fund KCE Repor
Page 22 and 23:
Page 24 and 25:
Page 26 and 27:
Page 28 and 29:
10 Special Solidarity Fund KCE Repo
Page 30 and 31:
Page 32 and 33:
Page 34 and 35:
Page 36 and 37:
Page 38 and 39:
Page 40 and 41:
Page 42 and 43:
Page 44 and 45:
Page 46 and 47:
Page 48 and 49:
Page 50 and 51:
Page 52 and 53:
Page 54 and 55:
Page 56 and 57:
Page 58 and 59:
Page 60 and 61:
Page 62 and 63:
Page 64 and 65:
Page 66 and 67:
Page 68 and 69:
Page 70 and 71:
Page 72 and 73:
Page 74 and 75:
Page 76 and 77:
Page 78 and 79:
Page 80 and 81:
Page 82 and 83:
Page 84 and 85:
Page 86 and 87:
Page 88 and 89:
Page 90 and 91:
Page 92 and 93:
Page 94 and 95:
Page 96 and 97:
Page 98 and 99:
Page 100 and 101:
Page 102 and 103:
Page 104 and 105:
Page 106 and 107:
Page 108 and 109:
Page 110 and 111:
Page 112 and 113:
Page 114 and 115:
Page 116 and 117:
Page 118 and 119:
100 Special Solidarity Fund KCE Rep
Page 120 and 121:
Page 122 and 123:
Page 124 and 125:
Page 126 and 127:
Page 128 and 129:
Page 130 and 131:
Page 132 and 133:
Page 134 and 135:
Page 136 and 137:
Page 138 and 139:
Page 140 and 141:
Page 142 and 143:
Page 144 and 145:
Page 146 and 147:
Page 148 and 149:
Page 150 and 151:
Page 152 and 153:
Page 154 and 155:
Page 156 and 157:
Page 158 and 159:
Page 160 and 161:
Page 162 and 163:
Page 164 and 165:
Page 166 and 167:
Page 168 and 169:
Page 170 and 171:
Page 172 and 173: 154 Special Solidarity Fund KCE Rep
Page 230 and 231: Wettelijk depot : D/2010/10.273/44
Page 232 and 233: 37. HTA Magnetische Resonantie Beel
Page 234: 108. Tiotropium in de behandeling v
show all

Optimalisatie van de werkingsprocessen van het Bijzonder ... - KCE

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?